News

Uses of Florbetapir PET Scans Set to Take Shape


 

Neurologists are beginning to get their feet wet prescribing the recently approved PET beta-amyloid imaging agent florbetapir (Amyvid), which is now under consideration for Medicare coverage. In this video, our reporter Michele Sullivan takes you through the process of an Amyvid PET scan, which can help rule out Alzheimer’s disease as a cause of cognitive decline.

Recommended Reading

Changing How We Prescribe Antipsychotics for Dementia
MDedge Psychiatry
Olanzapine Weight Gain May Start in the Brain
MDedge Psychiatry
More Evidence Confirms Relevance of Risk Allele to Schizophrenia
MDedge Psychiatry
Social Stigma Punishes All Areas of Alzheimer's Care
MDedge Psychiatry
Clinical, Social Barriers Cripple Adequate Alzheimer's Care
MDedge Psychiatry
When Societal Pressures Warp Creativity
MDedge Psychiatry
Alzheimer's Imaging Agent Considered for Medicare Coverage
MDedge Psychiatry
Drugs Set for Testing in Alzheimer's Prevention Trial
MDedge Psychiatry
Ahead of the Journals: Discontinuing Risperidone in AD
MDedge Psychiatry
Omega-3 fatty acids for psychiatric illness
MDedge Psychiatry